Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
atai Life Sciences (ATAI) company Recognify Life Sciences has reported that its Phase IIb trial of oral compound,…
France launches campaign to curb overuse of anxiety and sleep medications
Amid rising concern over long-term use and side effects, France has launched a national campaign to raise awareness…